Clinical trial
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With…
NCT00038246 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038246 |
|---|---|
| Title | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma |
| Official title | Phase I/II Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma (AI-PCa) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Estramustine, Thalidomide, Paclitaxel (Taxol) |
| Enrollment | 40 |
| Start date | Oct 1, 2000 |
| Primary completion | Feb 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | May 30, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: